Stop shingles in its tracks

Journal of Family Practice

Volumn 58, Issue 10, 2009, Pages 531-534

  Lang, Pierre Olivier ^a   Hasse, Yasmine ^a   Michel, Jean Pierre ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; FAMCICLOVIR; PLACEBO; PREDNISONE; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ANTICHOLINERGIC SYNDROME; ANTIVIRAL THERAPY; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; ORTHOSTATIC HYPOTENSION; PAIN; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION;

AGED; ANALGESICS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PRACTICE GUIDELINES AS TOPIC;

EID: 70350145305     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Centers for Disease Control and Prevention. Shingles disease - questions and answers (herpes zoster). Available at http://www.cdc.gov/vaccines/vpd-vac/ shingles/dis-faqs.htm. Accessed September 1, 2009.
2. Wareham DW, Breuer J. Herpes zoster. BMJ. 2007;334:1211-1215.
3. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571-575.
4. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26-33.
5. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24:1308-1314. (Pubitemid 43222038)
6. Chidiac C, Buxelles J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001;33:62-69. (Pubitemid 32554504)
7. Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57:1-30.
8. US Food and Drug Administration. FDA licenses new vaccine to reduce older Americans' risk of shingles. May 26, 2006. Available at www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108659.htm. Accessed September 1, 2009.
9. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003;326:748-750 (Pubitemid 36408042)
10. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(suppl 1):S1-S26.
11. Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62:1545-1551.
12. Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med. 1997;157:909-912.
13. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22:341-347. (Pubitemid 26056166)
14. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546-1553.
15. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123:89-96.
16. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13:327-331. (Pubitemid 27280025)
17. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376-383.
18. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
19. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317-325. (Pubitemid 46768588)
20. Lu P, Euler GL, Jumaan AO, et al. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009;27:882-887.
21. Centers for Disease Control and Prevention. Herpes zoster - vaccine Q&As for providers. Available at: http://www.cdc.gov/vaccines/vpd-vac/ shingles/vac-faqs-hcp.htm. Accessed September 1, 2009.